Nally 9,018 views 11 citations Perspective 04 October 2024 A novel class of oral, non-immunosuppressive, beta cell-targeting, TXNIP-inhibiting T1D drugs is emerging Gu Jing , 1 more and Anath Shalev 7,895 views 11 citations Original Research 30 August 2024 Engineered IRES-mediated promoter-free insulin-producing cells reverse hyperglycemia Yumin Li , 8 more and Bo Sun 5,225 views 3 citations Original Research 01 August 2024 Abnormal late postprandial glucagon response in type 1 diabetes is a function of differences in stimulated C-peptide concentrations Lingyu Zhang , 5 more and Mei Zhang 4,072 views 8 citations Original Research 09 July 2024 Prediction of personalised postprandial glycaemic response in type 1 diabetes mellitus Xin Xiong , 3 more and Heng Su 4,865 views 8 citations Original Research 09 February 2024 Preserved C-peptide is common and associated with higher time in range in Chinese type 1 diabetes Wei Liu , 11 more and Linong Ji 3,968 views 1 citations Original Research 08 February 2024 Advances in risk predictive performance of pre-symptomatic type 1 diabetes via the multiplex Antibody-Detection-by-Agglutination-PCR assay Devangkumar Tandel , 4 more and Cheng-ting Tsai 4,334 views 4 citations Loading
Grand Central Life & Style
CYP2E1 variants affect NAPQI production rates
This matters enormously for peptide research
Following nerve injury, NOS inhibitors are reported to attenuate the behavioral signs of neuropathic pain in neuropathic models indicating the importance of NO in maintenance of neuropathic pain 46,47
